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Abstract of thesis
In this doctoral dissertation, Wang Y describes the pathophysiology of non-alcoholic steatohepatitis. The content 
is summarized as follows. 
Purpose 
Non-alcoholic steatohepatitis (NASH) is the most common chronic liver disease in adults. Epidemiologic and 
animal studies implicate overconsumption of dietary sugar, particularly fructose, is suspected to be a critical 
contributor to the development of NASH. Carbohydrate response element binding protein (ChREBP) is a key 
transcriptional regulator of de novo lipogenesis (DNL). ChREBP is reported as an important factor in response to 
fructose-induced hepatic steatosis and hepatitis by regulating both gene expression and secretion of fibrosis growth 
factor 21 (FGF21). However, mechanisms underlying fructose modulation of ChREBP-FGF21 axis are still unclear. 
cAMP responsive element binding protein H(CREBH) is a membrane-bound transcription factor which regulates 
lipid metabolism. CREBH and peroxisome proliferator-activated receptor alpha (PPARa) co-activate hepatic Fgf21 
expression and exert effects on energy metabolism through the modulation of plasma FGF21 levels. Previously, the 
group reported that deficiency of CREBH exacerbates non-alcoholic fatty liver disease (NAFLD) and NASH.Here, 
the author investigated to define if CREBH affects ChREBP-FGF21 axis in response to hepatic fructose 
metabolism. 
Material and method 




(HFruD) or 60% fructose water (60% FW) for 8 weeks or 24 hours, respectively. Body weight, liver weight, plasma 
parameters, FGF21 levels, liver TC and TG content of mice were measured. The author performed RT-PCR, 
western blot,chromatin immunoprecipitation assay (ChIP) using liver samples. Liver sections were stained by 
haematoxylin and eosin (H&E) staining or Masson trichrome (M&T) staining. For in vitro experiments, 293 cells 
were transfected using lipofectamine 3000 and immunoprecipitated by specific plasmids to check protein-protein 
interactions. Mouse primary hepatocytes were isolated from the and challenged with fructose or glucose. 
 
Results 
The author fed WT mice and CKO mice HFruD for 8 weeks and found that CKO mice showed severer fatty liver 
and liver injury. The loss of CREBH led a significant reduction of ChREBP protein level and Chrebpβ gene 
expression as well as Fgf21 gene expression and its secretion in circulation. Furthermore, the author revealed that 
chromatin ChIP suggested the recruitment of ChREBP to ChoRE reporter on FGF21 promoter was significant 
lower in CKO mice compare with that of WT mice after 8 weeks HFruD. By WGA purification, the author found 
that one of ChREBP post-transcriptional modifications (PTMs), O-GlcNAcylation was reduced both in CKO mice 
and CREBH knockdown mouse primary hepatocytes. In addition, the author found that both exogenous and 
endogenous CREBH combined with O-Linked N -Acetylglucosamine Transferase (OGT) by using 293A cell line 
and mouse primary hepatocytes under high fructose condition. And exogenous CREBH increased the interaction 
between ChREBP and OGT. Taken together, the data suggested that CREBH plays a crucial role in fructose 
induced ChREBP-FGF21 axis hepatic fructose metabolism. 
 
Discussion 
The author revealed a novel role of CREBH-mediated adaptive pathway that prevnt the liver from fatty liver 
change and liver damage in response to fructose consumption. In vivo and in vitro data suggested that CREBH 
plays an essential role on O-GlcNAcylation induced ChREBP activation, which lead to the upregulation of FGF21 
gene expression and secretion in response to fructose influx to prevent the liver from fructose overconsumption 
induced fatty liver change and liver injury. 
Abstract of assessment result 
(General Comments) 
The author revealed a novel gene and nutrition interaction as a survival mechanism. Also, the author identified a 
new PTM of CREBH in response to fructose which allows CREBH to reduce fructose triggered ChREBP induced 
TG accumulation, mice with genetic defects in Crebh might progress to NASH or even cirrhosis likely due to the 
reduction of FGF21 secretion. In this article, the findings provide convincing evidences that CREBH plays a crucial 
role in hepatic lipid metabolism.  The data also implicates that CREBH could be a potential therapeutic target for 
NAFLD, NASH or cirrhosis.The final examination committee conducted a meeting as a final examination on Jan. 8, 
2020. The applicant provided an overview of dissertation, addressed questions and comments raised during Q&A 
session. All of the committee members reached a final decision that the applicant has passed the final 
examination.The final examination committee approved that the applicant is qualified to be awarded Doctor of 
Philosophy in Medical Sciences. 
